NCT06011317View on ClinicalTrials.gov

A Study of EDG-7500 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

May 23, 2024

Study Completion Date

June 20, 2024

Conditions
Healthy Subjects
Interventions
DRUG

EDG-7500

EDG-7500 is administered orally once daily

DRUG

Placebo

Placebo is administered orally once daily

Trial Locations (2)

68502

Celerion, Lincoln

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Edgewise Therapeutics, Inc.

INDUSTRY